DEPO-SUBQ PROVERA 104 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Depo-subq Provera 104, and what generic alternatives are available?
Depo-subq Provera 104 is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in DEPO-SUBQ PROVERA 104 is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Depo-subq Provera 104
A generic version of DEPO-SUBQ PROVERA 104 was approved as medroxyprogesterone acetate by BARR on August 9th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DEPO-SUBQ PROVERA 104?
- What are the global sales for DEPO-SUBQ PROVERA 104?
- What is Average Wholesale Price for DEPO-SUBQ PROVERA 104?
Summary for DEPO-SUBQ PROVERA 104
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 78 |
Clinical Trials: | 59 |
Patent Applications: | 4,238 |
DailyMed Link: | DEPO-SUBQ PROVERA 104 at DailyMed |
Recent Clinical Trials for DEPO-SUBQ PROVERA 104
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Oregon Health and Science University | Early Phase 1 |
Canadian Institutes of Health Research (CIHR) | Phase 4 |
Canadian Cancer Society (CCS) | Phase 4 |
Pharmacology for DEPO-SUBQ PROVERA 104
Drug Class | Progestin |
US Patents and Regulatory Information for DEPO-SUBQ PROVERA 104
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | DEPO-SUBQ PROVERA 104 | medroxyprogesterone acetate | INJECTABLE;SUBCUTANEOUS | 021583-001 | Dec 17, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DEPO-SUBQ PROVERA 104
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer | DEPO-SUBQ PROVERA 104 | medroxyprogesterone acetate | INJECTABLE;SUBCUTANEOUS | 021583-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DEPO-SUBQ PROVERA 104
See the table below for patents covering DEPO-SUBQ PROVERA 104 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 100473376 | ⤷ Sign Up | |
Poland | 203075 | ⤷ Sign Up | |
Peru | 20011322 | SUSPENSIONES ACUOSAS ESTABILIZADAS PARA USO PARENTERAL | ⤷ Sign Up |
Taiwan | I256310 | ⤷ Sign Up | |
Poland | 365793 | ⤷ Sign Up | |
Australia | 6737101 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DEPO-SUBQ PROVERA 104
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0113964 | 97C0037 | Belgium | ⤷ Sign Up | PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |